- Home
- EPSM vs YMAB Comparison
EPSM vs YMAB Comparison
Compare EPSM & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- YMAB
- Stock Information
- Founded
- EPSM 2010
- YMAB 2015
- Country
- EPSM China
- YMAB United States
- Employees
- EPSM N/A
- YMAB N/A
- Industry
- EPSM
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- YMAB Health Care
- Exchange
- EPSM Nasdaq
- YMAB Nasdaq
- Market Cap
- EPSM 185.6M
- YMAB 192.4M
- IPO Year
- EPSM 2025
- YMAB 2018
- Fundamental
- Price
- EPSM $16.00
- YMAB $4.79
- Analyst Decision
- EPSM
- YMAB Buy
- Analyst Count
- EPSM 0
- YMAB 10
- Target Price
- EPSM N/A
- YMAB $17.00
- AVG Volume (30 Days)
- EPSM 217.4K
- YMAB 154.8K
- Earning Date
- EPSM 01-01-0001
- YMAB 08-11-2025
- Dividend Yield
- EPSM N/A
- YMAB N/A
- EPS Growth
- EPSM N/A
- YMAB N/A
- EPS
- EPSM 0.02
- YMAB N/A
- Revenue
- EPSM $12,518,070.00
- YMAB $88,658,000.00
- Revenue This Year
- EPSM N/A
- YMAB N/A
- Revenue Next Year
- EPSM N/A
- YMAB $15.15
- P/E Ratio
- EPSM $676.16
- YMAB N/A
- Revenue Growth
- EPSM N/A
- YMAB 4.92
- 52 Week Low
- EPSM $4.23
- YMAB $3.55
- 52 Week High
- EPSM $29.76
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- YMAB 56.08
- Support Level
- EPSM N/A
- YMAB $4.64
- Resistance Level
- EPSM N/A
- YMAB $5.01
- Average True Range (ATR)
- EPSM 0.00
- YMAB 0.25
- MACD
- EPSM 0.00
- YMAB 0.06
- Stochastic Oscillator
- EPSM 0.00
- YMAB 60.20
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.